Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes
| Autor: | Montien Pesee, Narudom Supakalin, Prawat Padoongcharoen, Srichai Krusun, Komsan Thamronganantasakul, Chunsri Supaadirek |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Blood Platelets Cancer Research medicine.medical_specialty Uterine cervical cancer Epidemiology Uterine Cervical Neoplasms Hematologic toxicity Disease-Free Survival Hemoglobins Leukocyte Count Overall survival medicine Humans In patient Stage (cooking) Aged Retrospective Studies business.industry Public Health Environmental and Occupational Health Chemoradiotherapy Middle Aged Creatine Combined Modality Therapy Surgery Concurrent chemoradiotherapy Treatment Outcome Skin toxicity Withholding Treatment Oncology Treatment interruption Female Cisplatin business |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 15:5653-5657 |
| ISSN: | 1513-7368 |
| DOI: | 10.7314/apjcp.2014.15.14.5653 |
| Popis: | To evaluate factors which effect treatment interruption during concurrent chemoradiotherapy (CCRT) and overall survival in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital.Between January 2006 and December 2007, 107 patients with stage IB2-IVA as FIGO staging, 2000, were treated with CCRT in Srinagarind Hospital. Factors which caused treatment interruptions and impacted on overall survival were reviewed and analyzed.Twenty of 107 patients had treatment interruption during CCRT in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital. The causes of treatment interruption were as follows: hematologic toxicity was found in 16 of 20 cases, 12 cases with grade 2 and 4 cases with grade 3; three of 20 cases had gastrointestinal toxicities, 1 case with grade 2 and 2 cases with grade 3; one case had grade 3 skin toxicity. The mean total treatment time of the uninterrupted and interrupted groups were significantly different (78.98 days vs 161.80 days, p0.001). The patients who could tolerate ≥5 cycles of cisplatin administration had significantly higher mean white blood counts (WBC) (9,769 cells/ mm3 vs 7,141 cells/mm3, p=0.02). The mean initial hemoglobin (Hb) in the uninterrupted group was significantly higher than the interrupted group (11.5 mg% vs 10.3 mg%, p=0.03). Other factors including age, KPS, initial platelets, initial serum creatinine levels showed no statistical significance. The 3-year overall survival of the uninterrupted group was better than in the interrupted group (78.6% vs 55.0%, p=0.03).The initial Hb and WBC levels were significantly correlated with treatment interruption during CCRT in patients with uterine cervical cancer. The 3-year overall survival of the uninterrupted group was significantly better than interrupted group. These factors may then be used indirectly to predict the outcomes of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|